NCT00017199已完成2 期
Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 4
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic neuroendocrine tumors.
详细描述
OBJECTIVES:
- Determine the objective response rate of patients with metastatic neuroendocrine tumors treated with bortezomib.
- Determine the toxicity of this drug in this patient population.
- Determine the pharmacodynamics to correlate proteasome inhibition and efficacy of this drug in this patient population.
OUTLINE: This is a multicenter study.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond CR.
PROJECTED ACCRUAL: A total of 16-25 patients will be accrued for this study within 6 months.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
2 期
Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic NeuroblastomaNeuroblastomaNCT00024193Children's Cancer and Leukaemia Group
已完成
2 期
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic OsteosarcomaSarcomaNCT00005625Memorial Sloan Kettering Cancer Center
已完成
2 期
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast CancerBreast CancerNCT00003352NSABP Foundation Inc89
已完成
2 期
PS-341 in Treating Patients With Metastatic Kidney CancerKidney CancerNCT00017329Memorial Sloan Kettering Cancer Center
已完成
1 期
PS-341 in Treating Patients With Advanced Solid Tumors or LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol SpecificLymphomaNCT00004002NYU Langone Health